Ftse Mib
33.887,05
0,62%
DAX
18.996,63
0,89%
S&P 500
5.724,63
0,11%
NASDAQ
18.071,85
0,54%
Bitcoin
63.564,03
0,37%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Mallinckrodt Plc (MNK) Mallinckrodt Plc (MNK) Notizie

MNK

Mallinckrodt (MNK)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:MNK
DataOraFonteTitoloSimboloCompagnia
17/09/202412:50PR Newswire (US)Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use® Certification of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ InjectorNYSE:MNKMallinckrodt Plc
03/09/202409:45PR Newswire (US)THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR)NYSE:MNKMallinckrodt Plc
06/08/202412:45PR Newswire (US)Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year GuidanceNYSE:MNKMallinckrodt Plc
06/08/202412:35PR Newswire (US)Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector in the U.S.NYSE:MNKMallinckrodt Plc
05/08/202413:00PR Newswire (US)Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 MillionNYSE:MNKMallinckrodt Plc
01/08/202414:59PR Newswire (US)Mallinckrodt to Report Earnings Results for Second Quarter 2024NYSE:MNKMallinckrodt Plc
05/06/202412:45PR Newswire (US)Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 European Association for the Study of the Liver (EASL) CongressNYSE:MNKMallinckrodt Plc
18/05/202413:00PR Newswire (US)Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 Digestive Disease Week® (DDW)NYSE:MNKMallinckrodt Plc
09/05/202412:45PR Newswire (US)Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year GuidanceNYSE:MNKMallinckrodt Plc
26/03/202421:01PR Newswire (US)Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 GuidanceNYSE:MNKMallinckrodt Plc
11/03/202411:52PR Newswire (US)Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American PatientsNYSE:MNKMallinckrodt Plc
04/03/202412:45PR Newswire (US)Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty BrandsNYSE:MNKMallinckrodt Plc
01/03/202414:50PR Newswire (US)Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ InjectorNYSE:MNKMallinckrodt Plc
02/02/202414:45PR Newswire (US)Mallinckrodt Announces Board of Directors and Leadership UpdatesNYSE:MNKMallinckrodt Plc
22/01/202412:52PR Newswire (US)Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin) for Injection at the Society of Critical Care Medicine (SCCM) 2024 Critical Care CongressNYSE:MNKMallinckrodt Plc
01/11/202311:45PR Newswire (US)Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2023 Scientific MeetingNYSE:MNKMallinckrodt Plc
26/10/202312:53PR Newswire (US)Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023NYSE:MNKMallinckrodt Plc
30/08/202317:54PR Newswire (US)Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing OperationsNYSE:MNKMallinckrodt Plc
30/06/202300:53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:MNKMallinckrodt Plc
26/06/202312:48Edgar (US Regulatory)Current Report Filing (8-k)NYSE:MNKMallinckrodt Plc
23/06/202322:43Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NYSE:MNKMallinckrodt Plc
16/06/202323:05Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NYSE:MNKMallinckrodt Plc
31/05/202322:07Edgar (US Regulatory)Specialized Disclosure Report (sd)NYSE:MNKMallinckrodt Plc
30/05/202322:32Edgar (US Regulatory)Statement of Ownership (sc 13g)NYSE:MNKMallinckrodt Plc
09/05/202312:52Edgar (US Regulatory)Quarterly Report (10-q)NYSE:MNKMallinckrodt Plc
05/04/202322:34Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NYSE:MNKMallinckrodt Plc
05/04/202322:32Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NYSE:MNKMallinckrodt Plc
22/01/202320:00PR Newswire (US)Mallinckrodt Presents New TERLIVAZ® (terlipressin) for Injection Data on Hepatorenal Syndrome (HRS) Reversal at the Society of Critical Care Medicine (SCCM) 2023 Critical Care CongressNYSE:MNKMallinckrodt Plc
12/01/202312:45PR Newswire (US)Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific OfficerNYSE:MNKMallinckrodt Plc
16/11/202212:52PR Newswire (US)Mallinckrodt Announces 2022 Advancing Extracorporeal Photopheresis Immunomodulation Investigator AwardNYSE:MNKMallinckrodt Plc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:MNK

La tua Cronologia

BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
TEN
Tenaris
BIT
ENEL
Enel
BIT
RACE
Ferrari NV
BIT
MONC
Moncler
BIT
SPM
Saipem
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
IVG
Iveco Group NV
BIT
CPR
Davide Campari
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network